biosytech
MEDICAL LABORATORY

BML487890

Laboratory Investigation Report

Name	:	Ms. TEOPISTA NAMIREMBE	**Ref No.**	:	44869
DOB	:	29/11/1993	**Sample No.**	:	2411498673
Age / Gender	:	30 Y / Female	**Collected**	:	11/11/2024 12:10
Referred by	:	CITICARE MEDICAL CENTER	**Registered**	:	11/11/2024 23:21
Centre	:	CITICARE MEDICAL CENTER	**Reported**	:	12/11/2024 00:14

BIOCHEMISTRY

Test	Result	Flag	Unit	Reference Range	Methodology
URIC ACID (SERUM)	3		mg/dL	2.4 - 5.7 Please note change. Source: Roche IFU.	Enzymatic colorimteric assay
C-REACTIVE PROTEIN (CRP)	< 0.6		mg/L	< 5.0 Please note change. Source: Roche IFU.	Particle-enhanced immunoturbidimetric assay

INTERPRETATION NOTES :

1. CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
2. C-reactive protein is the classic acute phase protein in inflammatory reactions.
3. CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
4. CRP response may be less pronounced in patients suffering from liver disease.
5. CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection.

Sample Type : Serum

End of Report

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

HARSHAD MANIKANDAN
Laboratory Technician
Printed on: 12/11/2024 00:18

This is an electronically authenticated report

P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com

biosytech
MEDICAL LABORATORY

BML487890

Laboratory Investigation Report

Name	:	Ms. TEOPISTA NAMIREMBE	**Ref No.**	:	44869
DOB	:	29/11/1993	**Sample No.**	:	2411498673
Age / Gender	:	30 Y / Female	**Collected**	:	11/11/2024 12:10
Referred by	:	CITICARE MEDICAL CENTER	**Registered**	:	11/11/2024 23:21
Centre	:	CITICARE MEDICAL CENTER	**Reported**	:	11/11/2024 23:49

HEMATOLOGY

Test	Result	Flag	Unit	Reference Range	Methodology
COMPLETE BLOOD COUNT (CBC)					
HEMOGLOBIN	9.5	L	g/dL	12 - 15.5	Photometric
RBC COUNT	4.1		10^6/µL	3.9 - 5	Electrical Impedance
HEMATOCRIT	29.3	L	%	35 - 45	Calculation
MCV	70.9	L	fL	82 - 98	Calculation
MCH	23.1	L	pg	27 - 32	Calculation
MCHC	32.5		g/dL	32 - 37	Calculation
RDW	18.9	H	%	11.9 - 15.5	Calculation
RDW-SD	48.1		fL		Calculation
MPV	7.4	L	fL	7.6 - 10.8	Calculation
PLATELET COUNT	358		10^3/uL	150 - 450	Electrical Impedance
PCT	0.3		%	0.01 - 9.99	Calculation
PDW	16.5		Not Applicable	0.1 - 99.9	Calculation
NUCLEATED RBC (NRBC)^	0.2		/100 WBC		VCS 360 Technology
ABSOLUTE NRBC COUNT^	0.01		10^3/uL		Calculation
EARLY GRANULOCYTE COUNT (EGC)^	0		%		VCS 360 Technology
ABSOLUTE EGC^	0		10^3/uL		Calculation
WBC COUNT	4.8		10^3/µL	4 - 11	Electrical Impedance
DIFFERENTIAL COUNT (DC)					
NEUTROPHILS	39	L	%	40 - 75	VCS 360 Technology
LYMPHOCYTES	56		%	30 - 60	VCS 360 Technology
EOSINOPHILS	1		%	0 - 6	VCS 360 Technology
MONOCYTES	4		%	1 - 6	VCS 360 Technology
BASOPHILS	0		%	0 - 1	VCS 360 Technology
ABSOLUTE COUNT					
ABSOLUTE NEUTROPHIL COUNT	1.7		10^3/uL	1.6 - 8.25	Calculation
ABSOLUTE LYMPHOCYTE COUNT	2.7		10^3/uL	1.2 - 6.6	Calculation
ABSOLUTE MONOCYTE COUNT	0.3		10^3/uL	0.04 - 0.66	Calculation
ABSOLUTE EOSINOPHIL COUNT	0		10^3/uL	0 - 0.66	Calculation
ABSOLUTE BASOPHIL COUNT	0		10^3/uL	0 - 0.11	Calculation

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

HALEEM HAKKIM
Laboratory Technician
Printed on: 12/11/2024 00:18

This is an electronically authenticated report

P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com

biosytech
MEDICAL LABORATORY

BML487890

Laboratory Investigation Report

Name	:	Ms. TEOPISTA NAMIREMBE	**Ref No.**	:	44869
DOB	:	29/11/1993	**Sample No.**	:	2411498673
Age / Gender	:	30 Y / Female	**Collected**	:	11/11/2024 12:10
Referred by	:	CITICARE MEDICAL CENTER	**Registered**	:	11/11/2024 23:21
Centre	:	CITICARE MEDICAL CENTER	**Reported**	:	11/11/2024 23:49

HEMATOLOGY

Test	Result	Flag	Unit	Reference Range	Methodology
COMPLETE BLOOD COUNT (CBC)					

INTERPRETATION NOTES :

Please note update on CBC report format, reference ranges and method(Beckman Coulter).

Sample Type : *EDTA Whole Blood*

End of Report

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

HALEEM HAKKIM
Laboratory Technician
Printed on: 12/11/2024 00:18

This is an electronically authenticated report

P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com

biosytech
MEDICAL LABORATORY

BML487890

Laboratory Investigation Report

Name	:	Ms. TEOPISTA NAMIREMBE	**Ref No.**	:	44869
DOB	:	29/11/1993	**Sample No.**	:	2411498673
Age / Gender	:	30 Y / Female	**Collected**	:	11/11/2024 12:10
Referred by	:	CITICARE MEDICAL CENTER	**Registered**	:	11/11/2024 23:21
Centre	:	CITICARE MEDICAL CENTER	**Reported**	:	12/11/2024 00:14

IMMUNOLOGY

Test	Result	Flag	Unit	Reference Range	Methodology
RHEUMATOID FACTOR (QUANTITATIVE)	< 11.27		IU/mL	< 14.0 Please note change. Source: Roche IFU.	Immunoturbidimetry

INTERPRETATION NOTES :

Rheumatoid factors (RF) are a heterogeneous group of autoantibodies that are associated with the diagnosis of rheumatoid arthritis (RA), but can also be found in other inflammatory rheumatic and nonrheumatic conditions. This is a presumptive test, confirm with Anti-CCP test if needed.
Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

Sample Type : Serum

End of Report

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

HARSHAD MANIKANDAN
Laboratory Technician
Printed on: 12/11/2024 00:18

This is an electronically authenticated report

P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com